# BioNTech SE (BNTX) — Financial Analysis

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/BNTX/thesis · /stocks/BNTX/memo

## Financial Snapshot

---
source: coverage-next-full | ticker: BNTX | step: "04" | created: 2026-05-29
---

### Step 04 — Financial Snapshot
**BioNTech SE (BNTX) | FY2021–FY2024 | EUR Reporting Currency**

---

#### Income Statement Summary (IFRS, EUR millions)

| Metric | FY2021 | FY2022 | FY2023 | FY2024E |
|--------|--------|--------|--------|---------|
| **Revenue** | €18,698 | €17,328 | €3,819 | ~€2,400 |
| Cost of Sales | (€2,424) | (€2,877) | (€1,126) | ~(€700) |
| **Gross Profit** | €16,274 | €14,451 | €2,693 | ~€1,700 |
| Gross Margin | 87.0% | 83.4% | 70.5% | ~70% |
| R&D Expense | (€1,548) | (€1,890) | (€1,787) | ~(€1,900) |
| SG&A / G&A | (€546) | (€619) | (€526) | ~(€450) |
| **Operating Income** | €14,251 | €11,726 | €358 | ~(€680) |
| Operating Margin | 76.2% | 67.7% | 9.4% | neg. |
| Net Finance Income | €181 | €496 | €751 | ~€700 |
| **Pre-tax Income** | €14,432 | €12,222 | €1,109 | ~€20 |
| Income Tax | (€3,976) | (€2,797) | (€170) | ~(€50) |
| **Net Income** | €10,456 | €9,425 | €939 | ~(€30) |
| Net Margin | 55.9% | 54.4% | 24.6% | neg. |
| **EPS (diluted) — EUR** | €42.66 | €39.55 | €3.93 | ~(€0.15) |
| **EPS (diluted) — USD (approx.)** | ~$48 | ~$41 | ~$4.3 | ~$(0.16) |

*Note: FY2024 estimates based on Q1–Q3 2024 actuals + Q4 guidance. Net finance income is large due to interest on cash portfolio.*

---

#### Revenue Trajectory — Narrative

**FY2021 (Peak):** BioNTech's first full year of COVID vaccine revenue. BNT162b2 delivered to >120 countries; booster campaigns in H2 supercharged demand. The company generated €18.7B in revenue — more revenue than it had in its entire pre-COVID history combined, many times over. This single-year financial transformation is arguably the most dramatic in pharmaceutical history for a company of this size.

**FY2022 (Elevated but declining):** Booster campaigns, Omicron bivalent update, and government top-up orders kept revenue near the peak. Cash accumulation continued. Management began foreshadowing transition to oncology. Massive R&D investment ramp began.

**FY2023 (Revenue cliff):** The anticipated normalization hit sharply. Revenue fell 78% to €3.8B. COVID boosters transitioned to a standard commercial annual model at significantly lower volumes. Despite the steep decline, the company remained modestly profitable. Critically, the cash fortress held: net cash remained >€15B.

**FY2024 (Trough approached):** ~€2.4B estimated; COVID revenue stabilizes at endemic floor. Operating loss as R&D spend (~€1.9B) exceeds gross profit from COVID revenue alone. Net interest income (~€700M on the cash position) partially offsets operating losses. The company is essentially in "R&D investment mode" funded by its cash hoard.

---

#### Earnings Per Share Progression

| Year | Diluted EPS (EUR) | USD Approx. | YoY Change |
|------|-------------------|-------------|------------|
| 2020 | (€0.45) | ~$(0.50) | Pre-COVID loss |
| 2021 | €42.66 | ~$48 | +∞ (profit inflection) |
| 2022 | €39.55 | ~$41 | -7.3% |
| 2023 | €3.93 | ~$4.3 | -90.1% |
| 2024E | ~(€0.15) | ~$(0.16) | turn to loss |
| 2025E | ~(€2.50) | ~$(2.75) | deeper loss |
| 2026E | ~(€2.00) | ~$(2.20) | ongoing investment |

---

#### Balance Sheet Highlights (EUR millions)

| Item | FY2021 | FY2022 | FY2023 | 9M 2024 |
|------|--------|--------|--------|---------|
| Cash & Equivalents | €2,458 | €3,162 | €1,786 | ~€1,800 |
| Short-term Investments | €4,682 | €7,110 | €6,890 | ~€6,000 |
| Long-term Investments | €3,211 | €5,298 | €7,126 | ~€6,500 |
| **Total Cash + Investments** | **€10,351** | **€15,570** | **€15,802** | **~€14,300** |
| Total Assets | €15,287 | €21,382 | €20,785 | ~€19,000 |
| Total Debt | ~€0 | ~€0 | ~€0 | ~€0 |
| Shareholders' Equity | €10,741 | €16,162 | €16,082 | ~€14,500 |
| **Book Value/ADS (EUR)** | ~€44 | ~€69 | ~€68 | ~€65 |
| **Book Value/ADS (USD)** | ~$50 | ~$72 | ~$74 | ~$70 |

**Key observation:** BioNTech has essentially no financial debt. The balance sheet is a fortress of cash and high-quality liquid securities. This is the defining feature of the current investment case — market cap trades near or even below the cash position.

---

#### Cash Flow Statement Summary (EUR millions)

| Item | FY2021 | FY2022 | FY2023 | FY2024E |
|------|--------|--------|--------|---------|
| Operating Cash Flow | €10,788 | €8,534 | €1,087 | ~€200 |
| Capex | (€427) | (€893) | (€609) | ~(€500) |
| **Free Cash Flow** | €10,361 | €7,641 | €478 | ~(€300) |
| Share Repurchases | (€190) | (€1,560) | (€2,040) | ~(€1,000) |
| Dividends Paid | (€41) | (€196) | (€296) | ~(€150) |

---

#### Key Valuation Metrics (Approximate, as of late 2024 / early 2025)

| Metric | Value |
|--------|-------|
| Market Cap | ~$28–32B (~€25–29B) |
| Enterprise Value | ~$13–17B (market cap minus cash) |
| EV/Revenue (FY2024E) | ~5–7x |
| P/E (FY2024E) | N/M (near breakeven) |
| P/Cash (cash + investments) | ~1.0–1.2x |
| P/Book | ~0.95–1.1x |

**Critical valuation insight:** At ~1.0–1.2x cash, the market is valuing the entire oncology pipeline, the COVID revenue stream, and the mRNA platform at essentially zero to slightly negative. This is either a deep value opportunity or a value trap — depending on oncology pipeline success.

---

#### Transition Phase Financial Model

BioNTech is effectively running a **"cash to R&D" conversion model**:

```
COVID Cash Fortress (€15B+)
         ↓
Interest Income (~€700M/yr)     ←→ R&D Burn (~€1.9B/yr)
         ↓
Net Annual Burn: ~€1.2B in operating losses
         ↓
Plus Buybacks: ~€1-2B/year
         ↓
Cash Runway: ~8-10 years at current burn rate (before oncology revenues)
```

The key question: Will the oncology pipeline generate revenues before the cash position erodes to a level that constrains the company?

Management's guidance is that the cash position is sufficient to fund the full pipeline through multiple Phase 3 readouts. If BNT122 succeeds, partnership milestones and eventual commercial revenues would recharge the treasury.

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/BNTX/fundamental

## Navigation

- Overview: /stocks/BNTX
- Financials (this page): /stocks/BNTX/financials
- Thesis: /stocks/BNTX/thesis
- Investment Memo: /stocks/BNTX/memo
- Coverage universe: /stocks